The IP landscape surrounding the use of the CRISPR/Cas9 technology (and variants of it) can pose challenges for model generation. In a recent article published in DDN, Taconic Biosciences' Dr. Caroline Horizny explains the various CRISPR/Cas9 patents and the implications of obtaining patent rights when creating a new animal model for preclinical research:
"The CRISPR/Cas9 system, and variants of it, allows for in-vivo modifications including gene knockouts, certain knockins and the introduction of conditional alleles. One field which has seen exponential growth in the use of CRISPR/Cas9 is the generation of custom genetically engineered mouse and rat models. As compared to other genetic modification techniques, the use of CRISPR/Cas9 in the development of rodent models requires less time, effort and expense, enabling investigators to obtain a study cohort sooner and more cost-effectively."
Read the complete article and gain some clarity on this subject at:
![Guest Commentary: The unique IP landscape of CRISPR/Cas9-edited animal models](/content/dam/taconic/legacy/about-us/news/images/unique-ip-landscape-crispr-cas9-edited-animal-models.jpg)